MEZZION

mezzion-logo

Mezzion is a pharmaceuticals company that develops and discovers medicines.

#People #Website #More

MEZZION

Social Links:

Industry:
Health Care Medical Pharmaceutical

Founded:
2002-01-01

Address:
Deerfield, Illinois, United States

Country:
United States

Website Url:
http://www.mezzion.com

Total Employee:
101+

Status:
Active

Contact:
833-639-9466

Email Addresses:
[email protected]

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Domain Not Resolving Apache CPanel SSL


Current Employees Featured

dean-park_image

Dean Park
Dean Park CEO @ Mezzion
CEO

james-l-yeager_image

James L Yeager
James L Yeager Director @ Mezzion
Director

Official Site Inspections

http://www.mezzion.com

  • Host name: 198.185.159.145
  • IP address: 198.185.159.145
  • Location: New York United States
  • Latitude: 40.7157
  • Longitude: -74
  • Metro Code: 501
  • Timezone: America/New_York
  • Postal: 10013

Loading ...

More informations about "Mezzion"

Mezzion

Mezzion. Launching the world’s. largest Fontan clinical trial. Learn More about FUEL-2. Shaping the future of the Fontan community. We strive to discover, develop and deliver new hope for …See details»

Mission & Vision — Mezzion

At Mezzion, we have one simple goal: to build a better future for people living with single ventricle heart disease and Fontan circulation.See details»

History — Mezzion

Since our founding in South Korea in 2002, Mezzion, Co., Ltd has remained steadfast in our efforts as a rare disease company to develop new treatments for people with single ventricle heart disease and Fontan circulation.See details»

Mezzion Pharmaceuticals Announces Dr. Rahul Rathod as the …

Mar 4, 2024 · He will serve as Mezzion’s primary liaison to the FUEL-2 clinical research organization, study sites, and investigators. FUEL-2 is a Mezzion Pharmaceuticals-sponsored …See details»

Mezzion Raises $40 Million to Advance a First-to-Market …

Apr 28, 2023 · Rare disease focused Korean biotech Mezzion Pharma has secured nearly $40 million to fund FUEL-2, its confirmatory phase 3 clinical trial, along with future …See details»

Mezzion Pharma Raises Nearly $40M to Advance a …

Apr 25, 2023 · Mezzion Pharma is an innovation-driven pharmaceutical company that is focused on discovering, developing, and commercializing novel therapeutics in the field of rare pediatric diseases. Mezzion Pharma is a …See details»

The American Heart Association ("AHA") Recognizes Mezzion's …

Jan 9, 2020 · This AHA recognition highlights Mezzion's pioneering advance involving the treatment of Fontan patients with udenafil and Mezzion's dedication to the SVHD community," …See details»

Mezzion Appoints William Breitenbach as Chief Commercial …

Jun 15, 2021 · Mezzion Pharma Co., Ltd. is headquartered in Korea. Mezzion and its wholly owned subsidiary, Mezzion Pharmaceuticals, Inc., have administrative offices in Deerfield, …See details»

Contact Us - Mezzion

Please feel free to reach out to Mezzion including with inquiries about our udenafil clinical program. Corporate Headquarters 1 Bridge Plaza North - Suite 1008 - Fort Lee, New JerseySee details»

Mezzion Appoints William Breitenbach as Chief …

Jun 15, 2021 · SEOUL, Republic of Korea, June 15, 2021 /PRNewswire/ — Mezzion Pharma Co., Ltd. (140410.KQ), and Mezzion Pharmaceuticals, Inc. (individually or collectively, “Mezzion”), a leader in the field of rare single …See details»

Mezzion Appoints William Breitenbach as Chief Commercial

Jun 15, 2021 · Mezzion Pharma Co., Ltd., and Mezzion Pharmaceuticals, Inc., a leader in the field of rare single ventricle congenital heart disease and SVHD patients with Fontan circulation, is …See details»

Mezzion Pharma Raises $40M to Advance Fontan Treatment

Apr 26, 2023 · Mezzion Pharma, a rare disease-focused pharmaceutical company, announced that it has secured nearly $40M USD to fund FUEL-2, their confirmatory phase 3 clinical trial, …See details»

Community Resources - Mezzion

Mezzion is committed collaborating with key patient groups in the single ventricle heart disease space. Explore more about the work these groups are doing. Mended Little Hearts is providing …See details»

Mezzion Pharma Announces Positive Data Presented to FDA in …

Dec 21, 2021 · Mezzion Pharma Co., Ltd. is headquartered in Korea. Mezzion and its wholly owned subsidiary, Mezzion Pharmaceuticals, Inc., have administrative offices in Deerfield, …See details»

Mezzion Announces Re-Submission of New Drug ... - Markets Insider

Mar 28, 2021 · Mezzion Pharma Co., Ltd. is headquartered in Korea. Mezzion and its wholly owned subsidiary, Mezzion Pharmaceuticals, Inc., have administrative offices in Deerfield, …See details»

Mezzion Pharmaceuticals Announces Dr. Rahul Rathod of Boston …

Mar 2, 2024 · Mezzion Pharmaceuticals is a rare disease company conducting the confirmatory pivotal phase 3 clinical trial in Fontan subjects: The Fontan Udenafil Exercise Longitudinal …See details»

Mezzion Pharma Raises Nearly $40M to Advance a First-to-Market ...

Apr 24, 2023 · Mezzion Pharma ("Mezzion"), a rare disease focused pharmaceutical company, announced that it has secured nearly $40M USD to fund FUEL-2, their confirmatory phase 3 …See details»

Mezzion Announces Re-Submission of New Drug Application for …

Mar 29, 2021 · Mezzion Pharma Co., Ltd. is headquartered in Korea. Mezzion and its wholly owned subsidiary, Mezzion Pharmaceuticals, Inc., have administrative offices in Deerfield, …See details»

Mezzion Pharmaceuticals Announces Dr. Rahul Rathod of Boston …

FORT LEE, N.J., March 2, 2024 /PRNewswire/ -- Mezzion Pharmaceuticals is a rare disease company conducting the confirmatory pivotal phase 3 clinical trial in Fontan subjects: The …See details»